Officials from Novartis emphasized that the ribociclib-fulvestrant combination is the only one in the CDK4/6 inhibitor class to demonstrate an overall survival benefit when used in a first-line setting among postmenopausal women.
Postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2–) breast cancer treated initially with ribociclib plus fulvestrant saw overall survival (OS) benefits of nearly 16 more months than those treated with fulvestrant alone, according to new results of a groundbreaking trial.
Patients treated with ribociclib, a CDK4/6 inhibitor sold as Kisqali, achieved a 33% reduction in the risk of death and a medial OS of 67.6 months, according to the exploratory analysis from MONALEESA-3, which was unveiled May 4 during the European Society for Medical Oncology (ESMO) Breast Cancer Congress.
The initial study was presented at ESMO Congress 2019 and published in the New England Journal of Medicine. According to a statement from Novartis, which makes ribociclib and funded the study, the final OS analysis demonstrated a statistically significant OS benefit for ribociclib in combination with fulvestrant and a relative reduction in the risk of death by 28% vs fulvestrant alone in the full population (HR, 0.72; 95% CI: 0.568-0.924; P = .00455).
“MONALEESA-3 results continue to demonstrate the survival benefit of treatment with ribociclib for postmenopausal women with advanced breast cancer,” senior author Dennis J. Slamon, MD, director of clinical/translational research, University of California, Los Angeles Jonsson Comprehensive Cancer Center, said in a statement. “Whether partnered with fulvestrant or an aromatase inhibitor in the first-line setting, ribociclib offers oncologists a CDK4/6 inhibitor with consistent benefit in providing women with HR+/HER2– advanced breast cancer more quality time, regardless of their disease characteristics.”
Officials from Novartis emphasized that the ribociclib/fulvestrant combination is the only one in the CDK4/6 inhibitor class to demonstrate an OS benefit when used in a first-line setting. The combination has also produced the longest median OS, which has been reported in 3 phase 3 trials.
In MONALEESA-3, postmenopausal patients were randomized 2:1 to receive the ribociclib/fulvestrant combination or a placebo with fulvestrant. In this update, investigators reported an exploratory analysis of OS with additional follow-up, “allowing further characterization of long-term OS benefits of [ribociclib] in the [first-line] setting.”
At the data cutoff of January 12, 2022, the median follow-up for patients treated in the first-line setting was 70.8 months; 16.5% and 8.6% of patients remained in the treatment and placebo arms, respectively. An OS benefit was seen in those treated first-line with ribociclib vs placebo (median OS, 67.6 vs 51.8 months) for a hazard ratio of 0.67 (95% CI, 0.50-0.90). The OS rate at 5 years was 56.6% vs 42.1%, favoring ribociclib. Progression-free survival 2, which is time from randomization to second disease progression or death, also favored ribociclib (HR, 0.64). Results in the intent-to-treat and second-line populations were generally consistent with previous analyses, the investigators reported. No new adverse events were seen.
“It is a tremendous achievement to see such remarkable, consistent overall survival results from the MONALEESA clinical trial program, demonstrating how Novartis is transforming care for people with breast cancer as we continue to work toward cures,” said Jeff Legos, executive vice president, global head of oncology & hematology development. “The unique profile of Kisqali continues to be reinforced, with results from MONALEESA-3 pushing the boundaries of how using a Kisqali-combination treatment regimen can extend lives of postmenopausal women living with HR+/HER2– advanced breast cancer without compromising quality of life.”
Reference
Neven P, Fasching PA, Chia S, et al. Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL). Presented at: European Society for Medical Oncology Breast Cancer Congress; May 2-5, 2022; Berlin, Germany. Accessed May 8, 2022. Abstract LBA-4.
Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women
May 13th 2024A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Social Equity, Strong Health Care Systems Can Improve Advanced Breast Cancer Outcomes Globally
May 6th 2024Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More